Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06834217 · ClinicalTrials.gov registry record · NA

Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder

A NA study of Obsessive Compulsive Disorder (OCD), sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT06834217: Recruiting NA study of Obsessive Compulsive Disorder (OCD), sponsored by Yale University.

NCT06834217 is a NA study of Obsessive Compulsive Disorder (OCD) that is actively recruiting participants, run by Yale University. The registered enrollment target is 180 participants, below the 229-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06834217, a NA study of Obsessive Compulsive Disorder (OCD), is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

Obsessive-compulsive disorder (OCD) is associated with substantial impairments in quality of life and is among the most disabling psychiatric disorders. Exposure therapy is among the first-line of treatments for obsessive-compulsive disorder (OCD) . Extinction learning is thought to be a core mechanism of therapeutic exposure. Fear and safety signal learning are traditionally associated with activity and connectivity within the canonical corticolimbic "fear circuit", which includes the amygdala, medial prefrontal cortex (mPFC), and hippocampus. Transcranial direct current stimulation (tDCS) is a neuromodulation technology that can augment brain plasticity, learning, and memory. The proposed study will test if obsessive-compulsive disorder (OCD) is associated with inhibitory safety learning deficits and if transcranial direct current stimulation (tDCS) normalizes functional connectivity and safety signal processing to recover extinction deficits in obsessive-compulsive disorder (OCD).

Primary Outcome

Brain activity will be estimated with blood oxygen level-dependent (BOLD) response, which will be measured with magnetic resonance imaging (MRI).

Interventions

  • DEVICE Sham transcranial direct current stimulation
  • DEVICE Active transcranial direct current stimulation

Study Locations (1)

Connecticut

  • Temple Medical Center - New Haven

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2025-09-12
Est. Completion 2029-08-01
Phase NA
Yale University

1,492 total trials

What NCT06834217 shows while recruiting

NCT06834217 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 229-participant average among 12 other Obsessive Compulsive Disorder (OCD) trials with a reported enrollment target (21% lower).

The record links to 1 condition, with Obsessive Compulsive Disorder (OCD) appearing as the primary indexed condition, and to 2 interventions - of which Sham transcranial direct current stimulation is the first listed.

NCT06834217 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06834217 about?

NCT06834217 is a clinical study titled "Transcranial Direct Current Stimulation and Extinction in Obsessive Compulsive Disorder". Obsessive-compulsive disorder (OCD) is associated with substantial impairments in quality of life and is among the most disabling psychiatric disorders. Exposure therapy is among the first-line of treatments for obsessive-compulsive disorder (OCD) . Extinction learning is thought to be a core mechan...

What is the current status of trial NCT06834217?

This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2025-09-12. Estimated completion is 2029-08-01.

What conditions does trial NCT06834217 study?

This clinical trial studies the following conditions: Obsessive Compulsive Disorder (OCD).

What interventions are being tested in trial NCT06834217?

The interventions under investigation include: Sham transcranial direct current stimulation (DEVICE), Active transcranial direct current stimulation (DEVICE).

Who is sponsoring clinical trial NCT06834217?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06834217 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obsessive Compulsive Disorder (OCD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06834217's enrollment target sits among peer trials

180 4th of 12 higher than 9 of 12 other Obsessive Compulsive Disorder (OCD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obsessive Compulsive Disorder (OCD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06834217, the US trial registry maintained by the National Library of Medicine. NCT06834217 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.